Non-small-cell lung cancer restaging with transcervical extended mediastinal lymphadenectomy
|
|
- Violet Carson
- 6 years ago
- Views:
Transcription
1 European Journal of Cardio-thoracic Surgery 37 (2010) Non-small-cell lung cancer restaging with transcervical extended mediastinal lymphadenectomy Marcin Zieliński a, *, Łukasz Hauer a, Jolanta Hauer a, Tomasz Nabiałek b, Artur Szlubowski b, Juliusz Pankowski c a Department of Thoracic Surgery, Pulmonary Hospital, Zakopane, Poland b Department of Anesthesiology and Intensive Care, Pulmonary Hospital, Zakopane, Poland c Department of Pathology, Pulmonary Hospital, Zakopane, Poland Received 4 June 2009; received in revised form 26 October 2009; accepted 2 November 2009; Available online 30 December 2009 Abstract Background: To analyse a diagnostic yield of the transcervical extended mediastinal lymphadenectomy (TEMLA) in restaging of the mediastinal nodes after neoadjuvant chemo- or chemo-radiotherapy for non-small-cell lung cancer (NSCLC). Methods: From 1 January 2004 to 30 April 2009, 63 patients who underwent induction chemotherapy or chemo-radiotherapy for N2 and N2/3 metastatic nodes discovered preoperatively were restaged. There were 12 women and 51 men in the age group of (mean 57.8) years. There were 45 squamous cell carcinomas, 13 adenocarcinomas, one pleomorphic carcinoma and four NSCLCs. A total of 54 patients underwent neoadjuvant chemotherapy and nine chemoradiotherapy. Seven patients had mediastinoscopy before neoadjuvant therapy. As many as 34 patients underwent endobronchial ultrasound (EBUS), one patient underwent endo-oesophageal ultrasound (EUS) and 10 patients underwent combined EBUS/EUS. The diagnostic results of TEMLA were compared with the results of the largest published series of restaging patients. The results of subsequent thoracotomies after negative TEMLA were presented. Results: There were no serious complications or mortality after TEMLA. Metastatic nodes were discovered in 22 patients including three patients with N3 nodes and 19 patients with N2 nodes. Stations 7, 4R, 2R and 4L were the most prevalent. Of the 63 patients, 42 underwent subsequently thoracotomy. Resectability for negative TEMLA was 92.7%. There were 37 R0 resections and four R1 resections. There was no postoperative mortality, two bronchial fistulas were developed (after inferior bilobectomy and right pneumonectomy; the second one healed spontaneously) and there were no other serious complications. During thoracotomy with completion lymphadenectomy one false-negative result was found (single node in station 8). Sensitivity of TEMLA in the discovery of N2/3 nodes during restaging was 95.5%, specificity 100%, accuracy 98.3%, negative predictive value (NPV) 97.4% and positive predictive value (PPV) 100%. TEMLA was found to have significantly better sensitivity and NPV ( p < 0.05) than other series of restaging. During follow-up a local recurrence was noted in six of 37 (15.7%) patients after pulmonary resection. Conclusions: (1) The results of TEMLA in restaging of NSCLC (N2/3) patients after induction chemotherapy or chemo-radiotherapy were significantly better than those achieved with remediastinoscopy, EBUS and positron emission tomography/computed tomography (PET/CT). (2) The results of future studies will show if TEMLA should be considered the gold standard of mediastinal nodal restaging after neoadjuvant therapy in patients with NSCLC. # 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved. Keywords: Lung cancer; Mediastinal lymph nodes 1. Introduction The role of surgery in the multimodality treatment is still a matter of discussion. Until recently, neoadjuvant chemotherapy with subsequent pulmonary resection was regarded the standard of treatment for patients with N2 metastatic nodes discovered preoperatively [1 3]. However, this view has been changed currently and, according to the current Presented at the 17th European Conference on General Thoracic Surgery, Krakow, Poland, May 31 June 3, * Corresponding author. Address: ul. Gładkie 1, Zakopane, Poland. Tel.: ; fax: address: marcinz@mp.pl (M. Zieliński). Guidelines of American College of Chest Physicians (ACCP 2007), concurrent chemo-radiation is the recommended treatment in stage IIIA NSCLC. In NSCLC patients with N2 disease identified preoperatively, induction therapy followed by surgery is not recommended except as part of a clinical trial [4]. This statement was based on the results of two big multi-institutional trials presented recently (EORTC and North American Intergroup 0139 (RTOG 9309)), reporting no statistically significant difference of survival in patients randomised to the chemo-radiotherapy and induction chemo- or chemo-radiotherapy followed by surgery [5 7]. However, in these reports a substantial number of patients were found not to have a downstaging to N0 1 after induction therapy. The results of survival in patients /$ see front matter # 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved. doi: /j.ejcts
2 M. Zieliński et al. / European Journal of Cardio-thoracic Surgery 37 (2010) downstaged to N0 1 were significantly better than those in whom residual N2 metastatic nodes were found and in patients treated with radical chemo-radiotherapy without operation. In addition, recent systematic review and meta-analysis of the literature showed that the results of treatment of patients with NSCLC in stage IIIA were significantly better than those treated with surgery alone [8]. These controversies underline the critical role of proper restaging of the mediastinal nodes after neoadjuvant therapy and indicate that inclusion of surgery in the treatment protocol might be probably beneficial for the properly selected patients. The choice of the optimal methods used for restaging remains the problem for discussion. In this retrospective study, we report our results of restaging of the mediastinal nodes with the transcervical extended mediastinal lymphadenectomy (TEMLA), the new surgical technique introduced by our team in 2004 [9,10]. 2. Material and methods A total of 63 patients who underwent induction chemotherapy or chemo-radiotherapy for N2 and N2/3 metastatic nodes discovered preoperatively were restaged from 1 January 2004 to 30 April There were 12 women and 51 men in the age group (mean 57.8) years. There were 45 squamous cell carcinomas, 13 adenocarcinomas, one pleomorphic carcinoma and four NSCLCs. Among these patients: 54 patients underwent neoadjuvant chemotherapy and nine chemo-radiotherapy. Seven patients had mediastinoscopy before neoadjuvant therapy. The diagnosis of N2/3 metastatic involvement before neoadjuvant chemotherapy was confirmed with the positive results of invasive staging in 27 patients including seven patients who underwent mediastinoscopy, 16 patients who underwent EBUS and four patients who underwent EUS. In the other 36 patients the diagnosis of N2/3 was based on the results of chest CT. Of these 36 patients, four were initially staged in our hospital before EBUS and EUS became available and 30 patients were initially staged elsewhere. PET/CT was not performed in this group of patients. After completion of neoadjuvant therapy all patients were restaged with chest CT. In all patients from the study group there was a partial or complete response estimated by chest CT. Patients with bulky mediastinal nodes on restaging CT were included only if restaging with EBUS/EUS was negative. EBUS was performed in 34 patients, EUS in one patient and combined EBUS/EUS in 10 patients. All patients underwent TEMLA. The technique of TEMLA has been described in detail elsewhere and was used for restaging in a similar manner to the one used for primary staging [9,10]. In brief, it included a 5- to 8-cm collar incision in the neck, elevation of the sternal manubrium with a special retractor, bilateral visualisation of the laryngeal recurrent and vagus nerves and dissection of all mediastinal nodal stations except for the pulmonary ligaments nodes (station 9). Most of the procedure was performed in the open fashion, with the subcarinal and the peri-oesophageal nodes (stations 7 and 8) removed in the mediastinoscopy-assisted technique and the para-aortic and the pulmonary-window nodes (stations 6 and 5) removed in the video-assisted thoracic surgery (VATS), with the videothoracoscope inserted through the transcervical incision. In general, the mediastinal pleura was not violated and no drain was left in the mediastinum. All patients with negative results of TEMLA, who were fit enough, were referred to thoracotomy and radical pulmonary resection with completion systematic nodal dissection. Pathological examinations were performed in a standard haematoxilin/ eosin (HE) staining technique. The diagnostic yield of TEMLA was calculated in the standard manner. The results of restaging with TEMLA were compared with the results of the other biggest reported series of patients restaged with the other techniques. Statistical analysis was performed with the STATISTICA software package. Probability values were generated with the chi-square test and the Student s t-test or the Mann Whitney test. Probability values p < 0.05 were considered to be statistically significant. The study was approved by the Scientific Committee of our institution. 3. Results On restaging after neoadjuvant therapy performed in our hospital, metastatic nodes were found with EBUS in three patients, with EUS in one patient and in combined EBUS/EUS in two patients (overall six patients). These patients were not excluded from TEMLA because they were suspected to have very limited extent of the mediastinal nodal involvement without any other signs of metastatic spread. There were no serious complications or mortality after TEMLA. Metastatic nodes were discovered in 22 patients including three patients with N3 nodes and 19 patients with N2 nodes. Stations 7, 4R, 2R and 4L were most prevalent. In two out of six patients, who had positive results of restaging with EBUS or/and EUS, single metastatic encapsulated nodes were found on TEMLA, which were removed without laceration of the nodal capsule. These patients underwent subsequent pulmonary resection. In the other four patients, the multilevel metastatic nodal involvement was found. These patients were excluded from further thoracotomy. In two patients N3 supraclavicular nodes were found before neoadjuvant therapy. These nodes disappeared after neoadjuvant therapy, which was confirmed with TEMLA with simultaneous bilateral supraclavicular nodal dissection (there were no metastic nodes found). These two patients underwent subsequently pulmonary resection. The other five patients in whom N3 nodes were discovered on TEMLA did not undergo pulmonary resection. The downstaging rate to N0/1 achieved in 27 patients in whom metastatic N2/3 nodes were confirmed with pretreatment EBUS, EUS or mediastinoscopy was 59.3% (16/27 patients). Of the 41 patients, 38 had negative result of TEMLA and four patients with positive single station, encapsulated, completely removed N2 nodes, who underwent subsequentthoracotomy. Two of four of these patients were positive on EBUS/EUS, as described earlier; two others were negative on EBUS/EUS but positive on TEMLA. There were 41 pulmonary resections (and one exploratory thoracotomy) including: 20
3 778 M. Zieliński et al. / European Journal of Cardio-thoracic Surgery 37 (2010) Table 1 Types of pulmonary resections in 42 patients operated on after negative result of TEMLA. Type of pulmonary resection Number of patients Pneumonectomy 20 (10 right, 10 left) Sleeve-lobectomy 2 Bilobectomy 6 Lobectomy 13 Exploratory thoracotomy 1 Overall 42 patients who did not undergo thoracotomy were excluded from statistical analysis. During follow-up, local recurrence was noted in six of 41 (14.6%) patients after pulmonary resection. The comparison of diagnostic yield of restaging with TEMLA was compared with the results of the two largest reported series of remediastinoscopies (Table 3), the largest reported series of EBUS and PET/CT [11 14]. TEMLA was found to have significantly better sensitivity and NPV than in all other series (Table 4). Table 2 Diagnostic yield of TEMLA in restaging of NSCLC. Diagnostic parameter Value (%) Sensitivity 95.7 Specificity 100 Negative predictive value (NPV) 97.6 Positive predictive value (PPV) 100 Accuracy 98.4 Table 3 Results of remediastinoscopy. Author Number of patients % Sensitivity % Accuracy Rami-Porta et al. [18] De Waele et al. [24] De Leyn et al. [22] De Waele et al. [11] Marra et al. [12] pneumonectomies (10 right, 10 left), six bilobectomies, 13 lobectomies and two sleeve lobectomies (Table 1). Resectability for negative TEMLA was 92.7%. There were 37 R0 resections and four R1 resections. There was no postoperative mortality, while two bronchial fistulas developed (after inferior bilobectomy and right pneumonectomy; the second one healed spontaneously). There were no other serious complications after pulmonary resections. There were three patients with negative nodes on TEMLA who were not operated on because in one patient a cerebral metastasis was discovered and two other patients were in poor general state precluding thoracotomy. These two patients were marginal before TEMLA and deteriorated afterwards. During thoracotomy with completion lymphadenectomy, one false-negative result was found (single node of the station 8). Sensitivity of TEMLA in discovery of N2/3 nodes during restaging was 95.7%, specificity was 100%, accuracy was 98.4%, NPV was 97.6% and PPV was 100% (Table 2). Three 4. Comment The results of recently published randomised controlled trials of resection versus radiotherapy after induction chemotherapy or chemotherapy and radiotherapy showed no statistically significant difference of overall survival between surgery and radiotherapy [5,6]. The problems with results of both studies were that the results of patients with and without metastatic nodal downstaging after neoadjuvant therapy were reported together. In both studies the survival rates were significantly better in patients in whom downstaging to N0/1 was achieved than in patients with persistent N2 disease. In this selected group of patients with yn0/1 disease, there was a significant benefit of surgical treatment combined with induction chemotherapy or chemo-radiotherapy in comparison to the group of patients treated with chemo-radiotherapy without surgery. Similar conclusions were made by the authors of the other studies [15,16]. Unfortunately, the number of patients with persistent N2 nodes after induction treatment was exceedingly high in RTOG 9309 Study (36%) and in the EORTC study (58%), which most probably has affected the survival rates of the entire groups. The results of other studies showed that the results of treatment of patients with residual N2 nodes after neoadjuvant therapy were controversial, with reported 5-year survival rates in this group of patients ranging from 0% to 24% [17,18]. Therefore, the results and conclusions of both studies must be treated with caution. The unsatisfactory methods of restaging most probably negatively affected the results with final conclusion of RTOG 9309 Study group and EORTC group that chemo-radiotherapy was the standard treatment for future EORTC trials in stage IIIA NSCLC, which was repeated in the recent ACCP guidelines. Selection of the subgroup of patients with N2 nodes Table 4 Diagnostic yield of the largest reported series of restaging of NSCLC. De Waele et al. (group 1) Marra et al. (group 2) Herth et al. (group 3) Cerfolio et al. (group 4) Zieliński et al. (group 5) True positive (TP) True negative (TN) False positive (FP) False negative (FN) Overall Sensitivity (CI confidence intervals) (0.65, 0.72) (0.52, 0.61) (0.74, 0.77) (0.50, 0.71) (0.87, 0.96) Negative predictive value (NPV) (CI confidence intervals) (0.69, 0.73) (0.81, 0.85) (0.13, 0.20) (0.50, 0.71) (0.93, 0.98) Comparison of sensitivity: Groups 1 5, p = ; Groups 2 5, p = ; Groups 3 5, p = ; Groups 4 5, p = Comparison of NPV: Groups 1 5, p = ; Groups 2 5, p = ; Groups 3 5, p = ; Groups 4 5, p =
4 M. Zieliński et al. / European Journal of Cardio-thoracic Surgery 37 (2010) downstaged to yn0/1 nodes by means of reliable restaging method is therefore the most important issue. Currently available methods of restaging of the mediastinum include imaging studies, endoscopic studies and surgical techniques. Imaging studies include CT, which has relatively low diagnostic yield (sensitivity 41 59%, specificity 62 75% and accuracy 58 60%) and PET/CT with sensitivity 61 77%, specificity 85 90% and accuracy 78 83% [14,19]. PET/CT was found to be superior to CT (accuracy 89% vs 36% for stage I) [14]. Restaging with endoscopic techniques includes EBUS, EUS and combined EBUS/EUS. EBUS was used in the multiinstitutional report (Copenhagen, Boston, Heidelberg, Chiba) on 124 patients restaged after induction therapy with sensitivity 76%, specificity 100%, PPV 100%, NPV 20% and accuracy 77% [13]. The results of the other study with the use of EBUS were similar [19]. Diagnostic sensitivity and NPV of restaging with EBUS in our institution were 66.7% and 77.5%, respectively [20]. The use of restaging with EUS was described in the study by Annema et al. who performed EUS on 19 patients with sensitivity 75%, specificity 100% and accuracy 83% [21]. Surgical techniques of restaging include repeated mediastinoscopy (remediastinoscopy), VATS and TEMLA. Several series of remediastinoscopy are shown in Table 3. In general, remediastinoscopy seems to be a technique of moderate diagnostic yield with sensitivity of 61 83% (with the exception of sensitivity 29% in the study published by De Leyn et al. [22]). There was only one study on restaging with VATS. The study group included 70 patients but in 17 of them, procedures could not be completed due to adhesions. The authors reported sensitivity 75% and specificity 100% [23]. The current study is the first one presenting the use of TEMLA for the restaging of the mediastinal nodes. We did not rely on the restaging chest CT because of its low diagnostic yield. Our results of restaging with EBUS transbronchial needle aspiration (TBNA) published elsewhere showed sensitivity 66.7% and NPV 77.5% [20]. The results of our study show very high diagnostic yield of TEMLA in the restaging of the mediastinal nodes, with sensitivity of 95.7% and NPV of 97.6%. Despite some fibrosis of the mediastinum after induction therapy, especially in patients who underwent chemo-radiotherapy, the technical difficulties of an operation could be managed without any special problems. The full range of nodal dissection was performed in all patients and there were no intra-operative or postoperative complications. A false-negative result was found in only one patient with the omission of a single metastatic node from station 8. In the rest of the 62 of 63 patients the results of TEMLA were correct, which was proven by subsequent thoracotomy with completion lymphadenectomy. The use of TEMLA enabled proper selection of patients for thoracotomy with high resectability rate of 92.7%, no mortality and relatively low morbidity. The occurrence of two postoperative bronchial fistulas indicated a higher operative risk in patients undergoing pulmonary resection after neoadjuvant therapy. Our indications for TEMLA were very liberal, including two patients with proven N3 supraclavicular nodes discovered before neoadjuvant treatment. In our opinion there were no absolute contraindications to carry out TEMLA with bilateral supraclavicular nodal dissection performed with transcervical incision used for TEMLA. After obtaining negative results of TEMLA and supraclavicular nodal dissection, we decided that subsequent thoracotomy was justified. We are aware that this was not a standard way to treat patients at stage IIIB NSCLC. The downstaging rate to N0/1 in our study was 65.1%, very similar to the RTOG 9309 Study (64%). We must stress, however, that in 36 of 63 patients, the diagnosis of N2/3 nodal metastasis was based only on chest CT, without confirmation by invasive staging. Most of these patients were initially diagnosed in other institutions. At least in some of these patients, the pretreatment diagnosis of N2/3 might have been false positive. The downstaging rate to N0/1 achieved in patients in whom metastatic N2/3 nodes were confirmed with pretreatment EBUS, EUS or mediastinoscopy was 59.3%. The presented results of restaging with TEMLA are significantly better than those of any other diagnostic technique use for restaging, including such promising modalities as PET/CT and endoscopic ultrasonography (EBUS and EUS). However, our series of patients, including only seven of 63 patients who underwent mediastonoscopy before starting neoadjuvant treatment, was different from the series of de Waele et al. and Marra et al., including patients all of whom underwent previous mediastinoscopy. It must be stressed that in our experience the technical difficulty of restaging with TEMLA in patients with or without previous mediastinoscopy was quite similar. In none of the patients in our series who underwent previous mediastinoscopy was there any false-negative result during restaging. A prospective study comparing the results of restaging with CT, PET/CT, combined EBUS/EUS and TEMLA will soon be underway. The results of such a trial will provide the final answer as to whether TEMLA should be regarded the gold standard for restaging of the mediastinum after neoadjuvant therapy in patients with NSCLC instead of remediastinoscopy, which has been considered the current standard by the recent ESTS guidelines [25]. 5. Conclusions 1. The results of our study showed very high diagnostic value of TEMLA in the restaging of NSCLC (N2) patients after induction chemotherapy or chemo-radiotherapy, significantly better than those achieved with remediastinoscopy, EBUS and PET/CT. 2. The results of future studies will show if TEMLA should be considered the gold standard of mediastinal nodal restaging after neoadjuvant therapy in patients with NSCLC. References [1] Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330: [2] Roth JA, Fossella F, Komaki R, Ryan MB, Putnam Jr JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86: [3] Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992;53: [4] Robinson LA, Ruckdeschel JC, Wagner Jr H, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical prac-
5 780 M. Zieliński et al. / European Journal of Cardio-thoracic Surgery 37 (2010) tice guidelines (2nd edition) American College of Chest Physicians. Chest 2007;132(September (3 Suppl.)):243S 65S. [5] Van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G, European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-smallcell lung cancer. J Natl Cancer Inst 2007;99(March (6)): [6] Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC. North American Lung Cancer Intergroup Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA (pn2) nonsmall cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005;23 [Abstract 7014]. [7] Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC. North American Lung Cancer Intergroup Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA (pn2) nonsmall cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). Oncologist 2006;11:43. [8] Burdett S, Stewart LA, Rydzewska L. Systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in nonsmall cell lung cancer. J Thorac Oncol 2007;1: [9] Kuzdzal J, Zielinski M, Papla B, Szlubowski A, Hauer L, Nabialek T, Sosnicki W, Pankowski J. Transcervical extended mediastinal lymphadenectomy the new operative technique and early results in lung cancer staging. Eur J Cardiothorac Surg 2005;27:384. [10] Zieliński M. Transcervical extended mediastinal lymphadenectomy: results of staging in two hundred fifty-six patients with non-small cell lung cancer. J Thorac Oncol 2007;2: [11] De Waele M, Serra-Mitjans M, Hendriks J, Lauwers P, Belda-Sanchis J, Van Schil P, Rami-Porta R. Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. Eur J Cardiothorac Surg 2008;33: [12] Marra A, Hillejan L, Fechner S, Stamatis G. Remediastinoscopy in restaging of lung cancer after induction therapy. J Thorac Cardiovasc Surg 2008;135: [13] Herth FJ, Annema JT, Eberhardt R, Yasufuku K, Ernst A, Krasnik M, Rintoul RC. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. J Clin Oncol 2008;26: [14] Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131: [15] Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pn2 nonsmall-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21(May (9)): [16] Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ, Sugarbaker DJ. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70(December (6)): [17] Voltolini L, Luzzi L, Ghiribelli C, Paladini P, Di Bisceglie M, Gotti G. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg 2001;20: [18] Rami-Porta R, Mateu-Navarro M, Serra-Mitjans M, Hernández-Rodríguez H. Remediastinoscopy: comments and updated results. Lung Cancer 2003;42: [19] Kunst PW, Lee P, Paul MA, Senan S, Smit EF. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer. J Thorac Oncol 2007;2: [20] Szlubowski A, Herth Felix JF, Soja J, Kołodziej M, Figura J, Ćmiel A, Obrochta A, Pankowski J. Diagnostic yield of endobronchial ultrasoundguided needle aspiration in Non-Small Cell Lung Cancer restaging. Eur J Cardiothorac Surg, doi: /j.ejcts , in press. [21] Annema JT, Veseliç M, Versteegh MI, Willems LN, Rabe KF. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer 2003;42: [22] De Leyn P, Stroobants S, De Wever W, Lerut T, Coosemans W, Decker G, Nafteux P, Van Raemdonck D, Mortelmans L, Nackaerts K, Vansteenkiste J. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006;24(July (21)): [23] Jaklitsch MT. Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA-N2 NSCLC: results of CALGB J Clin Oncol 2005;23(16S):636s [Abstract 7065]. [24] De Waele M, Hendriks J, Lauwers P, Ortmanns P, Vanroelen W, Morel AM, Germonpré P, Van Schil P. Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg 2006;29: [25] De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M, Waller DA, Lerut T, Weder W. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:1 8. Editorial comment Mediastinal restaging: has the Holy Grail been found? Keywords: Lung cancer; Restaging; Induction therapy; TNM classification Different methods exist for mediastinal restaging after induction therapy. These include non-invasive techniques such as computed tomography (CT), magnetic resonance imaging and positron emission tomography; minimally invasive techniques comprising transbronchial needle aspiration (TBNA), endobronchial ultrasound (EBUS) and endoscopic oesophageal ultrasound (EUS); and invasive techniques as remediastinoscopy and video-assisted thoracic surgery (VATS) [1]. For restaging, non-invasive techniques have a rather low sensitivity and specificity and the falsenegative rate of minimally invasive techniques remains high. Repeat mediastinoscopy provides larger tissue biopsies but is technically more difficult and has a lower accuracy than a first mediastinoscopy. Experience with VATS for restaging is limited at the present time. Therefore, the best available method for restaging after induction therapy remains a highly debated issue as no currently available technique can be considered to be the gold standard. Nevertheless, downstaging is a major prognostic factor in patients with locally advanced non-small-cell lung cancer and patients with persisting mediastinal involvement after induction therapy have a poor prognosis [2 4].
Pneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationPatients with pathologically diagnosed involved mediastinal
MINI-SYMPOSIUM ON EMERGING TECHNIQUES FOR LUNG CANCER STAGING European Trends in Preoperative and Intraoperative Nodal Staging: ESTS Guidelines P. De Leyn, MF, PhD,* D. Lardinois, MD, P. Van Schil, MD,
More informationEndoscopic ultrasound-guided needle aspiration in lung cancer
ORIGINAL ARTICLE Artur Szlubowski 1, Marcin Zieliński 1, Joanna Figura 1, Jolanta Hauer 1, Witold Sośnicki 1, Juliusz Pankowski 2, Anna Obrochta 2, Magdalena Jakubiak 2 1 Department of Thoracic Surgery
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationVAMLA/TEMLA. Todd L. Demmy
VAMLA/TEMLA Todd L. Demmy Disclosures/ Questions Objectives - Staging Learn new lymphadenectomy (LA) results: Video-Assisted Mediastinal (VAMLA) Transcervical Extended Mediastinal (TEMLA) Compare with
More informationESTS guidelines for preoperative lymph node staging for non-small cell lung cancer
European Journal of Cardio-thoracic Surgery 32 (2007) 1 8 www.elsevier.com/locate/ejcts ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer Paul De Leyn a, *, Didier Lardinois
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationTranscervical extended mediastinal lymphadenectomy (TEMLA) for staging of non-small-cell lung cancer (NSCLC)
PRACA ORYGINALNA Marcin Zieliński 1, Łukasz Hauer 1, Jolanta Hauer 1, Juliusz Pankowski 2, Artur Szlubowski 3, Tomasz Nabiałek 3 1 Department of Thoracic Surgery, Pulmonary Hospital, Zakopane, Poland 2
More informationAccepted Manuscript. Indications for Invasive Mediastinal Staging for Non-small Cell Lung Cancer. Jules Lin, MD, Felix Fernandez, MD
Accepted Manuscript Indications for Invasive Mediastinal Staging for Non-small Cell Lung Cancer Jules Lin, MD, Felix Fernandez, MD PII: S0022-5223(18)31872-5 DOI: 10.1016/j.jtcvs.2018.07.027 Reference:
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationRevised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer
Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer Paul De Leyn 1, Christophe Dooms 2, Jaroslaw Kuzdzal 3, Didier Lardinois 4, Bernward Passlick 5, Ramon
More informationGUIDELINE RECOMMENDATIONS
European Journal of Cardio-Thoracic Surgery 48 (2015) 1 15 doi:10.1093/ejcts/ezv194 Cite this article as: Vilmann P, Frost Clementsen P, Colella S, Siemsen M, De Leyn P, Dumonceau J-M et al. Combined endobronchial
More informationCombined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer
TASK FORCE REPORT ESGE/ERS/ESTS GUIDELINES Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer European Society of Gastrointestinal Endoscopy (ESGE) Guideline,
More informationPreoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines
Highlighted Reports in European Lung Cancer Conference Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines Paul De Leyn 1, Christophe Dooms
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationThe Role of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Recurrent Non-small Cell Lung Cancer after Surgery
ORIGINAL ARTICLE The Role of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Recurrent Non-small Cell Lung Cancer after Surgery Seo Goo Han 1, Hongseok Yoo 1, Byung
More informationBronchoscopy and endobronchial ultrasound for diagnosis and staging of lung cancer
FRANCISCO AÉCIO ALMEIDA, MD, MS, FCCP Associate Staff Member, Director, Interventional Pulmonary Medicine Fellowship Program, Respiratory Institute, Cleveland Clinic, Cleveland, OH Bronchoscopy and endobronchial
More informationRecommendations 1 For mediastinal nodal staging in patients with suspected or proven non-small-cell lung cancer
Guideline 545 Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationMediastinoscopy. EBUS versus Mediastinoscopy?
Mediastinoscopy M.A. Paul, MD, PhD Dept of Surgery VU University Medical Center Amsterdam Perspectives in Lung Cancer, Amsterdam 9 10 March 2012 1 EBUS versus Mediastinoscopy? I had prepared for a Pro
More informationTranscervical uniportal pulmonary lobectomy
Original Article on Thoracic Surgery Page 1 of 6 Transcervical uniportal pulmonary lobectomy Marcin Zieliński 1, Tomasz Nabialek 2, Juliusz 3 1 Department of Thoracic Surgery, 2 Department of Anaesthesiology
More informationLes techniques invasives et minimalement invasives dans le staging du cancer bronchopulmonaire. V. Ninane, Hôpital Saint-Pierre, Bruxelles, Belgique
Les techniques invasives et minimalement invasives dans le staging du cancer bronchopulmonaire V. Ninane, Hôpital Saint-Pierre, Bruxelles, Belgique 1 Invasive Mediastinal Staging Purpose : to exclude Involvement
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationGENERAL THORACIC SURGERY
GENERAL THORACIC SURGERY Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non small cell lung cancer: Results of CALGB Protocol 39803
More informationSafety and Utility of Mediastinoscopy in Non-Small Cell Lung Cancer in a Complex Mediastinum
Safety and Utility of Mediastinoscopy in Non-Small Cell Lung Cancer in a Complex Mediastinum Brian E. Louie, MD, Seema Kapur, MD, Alexander S. Farivar, MD, Samuel J. Youssef, MD, Jed Gorden, MD, Ralph
More informationThe Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang,
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationVideo-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
More informationMediastinal restaging: EUS-FNA offers a new perspective
Lung Cancer (2003) 42, 311 318 Mediastinal restaging: EUS-FNA offers a new perspective Jouke T.Annema a, *, Maud Veseliç b, Michel I.M. Versteegh c, Luuk N.A. Willems a, Klaus F.Rabe a a Department of
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationIs surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement?
doi:10.1510/icvts.2011.267872 Interactive CardioVascular and Thoracic Surgery 13 (2011) 303-310 www.icvts.org Best evidence topic - Thoracic oncologic Is surgery indicated in patients with stage IIIa lung
More informationIs N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? No
2. Goldstraw P, Crowley J, Chansky K, et al ; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project:
More informationPrimary lung cancer is the most frequent cause of death
Original Article Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non Small-Cell Lung Cancer Sang-Won Um, MD, PhD,* Hong Kwan Kim, MD, PhD, Sin-Ho Jung, PhD, Joungho Han,
More informationVATS-lymph node dissection, staging and restaging in advanced malignancy/the Munich experience
Review Article Page 1 of 14 VATS-lymph node dissection, staging and restaging in advanced malignancy/the Munich experience Andreas Hiebinger 1, Dietmar Öfner-Velano 2, Johannes Bodner 1,3 1 Department
More informationKey words: CT scan; endobronchial ultrasound; integrated PET; lung cancer; staging
CHEST Original Research INTERVENTIONAL PULMONOLOGY Application of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Following Integrated PET/CT in Mediastinal Staging of Potentially Operable
More informationUtility of endobronchial ultrasound guided mediastinal lymph node biopsy in patients with non small cell lung cancer
GENERAL THORACIC SURGERY Utility of endobronchial ultrasound guided mediastinal lymph node biopsy in patients with non small cell lung cancer Benjamin E. Lee, MD, a,b Elaine Kletsman, PA, a,b John R. Rutledge,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationsurgical approach for resectable NSCLC
surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France 1933 Graham EA, Singer JJ.
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationSurgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease)
Eur J Cardio-thorac Surg (1996) 10:649-655 Springer-Verlag 1996 P. De Leyn P. Schoonooghe G. Deneffe D. Van Raemdonck W. Coosemans J. Vansteenkiste T. Lerut Surgery for non-small cell lung cancer with
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationThe currently used standard cervical mediastinoscopy (SCM)
ORIGINAL ARTICLE The Role of Extended Cervical Mediastinoscopy in Staging of Non-small Cell Lung Cancer of the Left Lung and a Comparison with Integrated Positron Emission Tomography and Computed Tomography
More informationPre- and intra-operative mediastinal staging in non-small-cell lung cancer
Published 8 March 2011, doi:10.4414/smw.2011.13168 Cite this as: Pre- and intra-operative mediastinal staging in non-small-cell lung cancer Didier Lardinois Universitätsspital Basel, Klinik für Thoraxchirurgie,
More informationLung Cancer staging Role of ENDOBRONCHIAL ULTRASOUND(Ebus) EBUS
Lung Cancer staging Role of ENDOBRONCHIAL ULTRASOUND(Ebus) Arvind Perathur Winter Retreat Feb 13 th 2011 Mason City IA 50401 EBUS Tiger now offers a very economical and environmentally friendly all electric
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationPredictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study
Moulla et al. Journal of Cardiothoracic Surgery (2019) 14:11 https://doi.org/10.1186/s13019-019-0831-0 RESEARCH ARTICLE Open Access Predictive risk factors for lymph node metastasis in patients with resected
More informationComparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,
More informationStaging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques
SERIES THORACIC ONCOLOGY Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques Georgios Stamatis Number 10 in the series Challenges and controversies in thoracic oncology
More informationTHE MAJORITY of patients with locally advanced lung
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pn2 Non Small-Cell Lung Cancer: A Multicenter Phase II Trial Daniel
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationPathologic staging of the mediastinal lymph nodes is
Mediastinoscopy: Still the Gold Standard Joseph B. Shrager, MD Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, and Veterans Administration
More informationLung Cancer 69 (2010) Contents lists available at ScienceDirect. Lung Cancer. journal homepage:
Lung Cancer 69 (2010) 60 65 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan EUS-FNA in the preoperative staging of non-small cell lung cancer M.
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationA pragmatic view of the usefulness of video-mediastinoscopy in the modern era
Surgical Technique on Mediastinal Surgery Page 1 of 7 A pragmatic view of the usefulness of video-mediastinoscopy in the modern era Marcello Migliore 1, Marco Nardini 1, Luke J. Rogers 2, Puwalani Vidanapathirana
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal
More informationTumors of the superior sulcus and central T4 tumors are an
ORIGINAL ARTICLE Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD,* Johan Vansteenkiste, MD, PhD, Yolande Lievens, MD, PhD, Dirk
More informationThree-arm robot-assisted thoracoscopic surgery for locally advanced N2 non-small cell lung cancer
Surgical Technique Three-arm robot-assisted thoracoscopic surgery for locally advanced N2 non-small cell lung cancer Xinghua Cheng, Chongwu Li, Jia Huang, Peiji Lu, Qingquan Luo Shanghai Chest Hospital,
More informationImproving the Inaccuracies of Clinical Staging of Patients with NSCLC: A Prospective Trial
Improving the Inaccuracies of Clinical Staging of Patients with NSCLC: A Prospective Trial Robert James Cerfolio, MD, FACS, Ayesha S. Bryant, MD, MSPH, Buddhiwardhan Ojha, MD, MPH, and Mohammad Eloubeidi,
More informationShort-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer Thomas W. Rice, MD, David J. Adelstein, MD, Jay P. Ciezki, MD, Mark E. Becker, MD, Lisa A. Rybicki, MS,
More informationComparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis
Chen et al. World Journal of Surgical Oncology (2018) 16:8 DOI 10.1186/s12957-018-1313-x REVIEW Open Access Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationS taging non-small lung cancer (NSCLC) is an important
696 LUNG CANCER Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study K G Tournoy, S Maddens, R Gosselin, G
More informationIndex. B Bronchogenic carcinoma, of left lung, Bronchogenic cysts, 150
A Acquired tracheo-oesophageal fistula, 198 199 Adenoid cystic carcinomas (ACC), 174 Anastomotic leaks, 194 Anterior mediastinal tumor, 143 tumor mass diagnosis, 32 33 Aortic valve implantation. See Transcatheter
More informationVideo-assisted thoracoscopic surgery in lung cancer staging
Review Article on Thoracic Surgery Page 1 of 7 Video-assisted thoracoscopic surgery in lung cancer staging Frederico Krieger Martins, Guilherme Augusto Oliveira, Juliano Cé Coelho, Márcio Chmelnitsky Kruter,
More informationAccurate mediastinal staging is a critical component
Endobronchial Ultrasound for Lung Cancer Staging: How Many Stations Should Be Sampled? Mark I. Block, MD Thoracic Surgery, Memorial Healthcare System, Hollywood, Florida Background. No guidelines exist
More informationProblems in the current diagnostic standards of clinical N1 non-small cell lung cancer
Department of Thoracic Oncology, National Cancer Centre Hospital East, Chiba, Japan Correspondence to: Dr T Hishida, Department of Thoracic Oncology, National Cancer Centre Hospital East, 6-5-1, Kashiwanoha,
More informationMinimally Invasive Mediastinal Staging of Non Small-Cell Lung Cancer: Emphasis on Ultrasonography-Guided Fine-Needle Aspiration
Endobronchial ultrasound and endoscopic ultrasound-guided lymph node biopsy may represent an alternative to cervical mediastinoscopy. Dorothy Fox, Rough Seas. Acrylic on canvas, 36ʺ 36ʺ. Minimally Invasive
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationStandardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer
Original Article on Transbronchial Needle Aspiration (TBNA) Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer Xu-Ru Jin 1 *, Min
More informationThe Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL
The Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL Conflict of Interest This presentation is supported by AstraZeneca Two main steps before
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationEndoscopic and Endobronchial Ultrasound Staging for Lung Cancer. Michael B. Wallace, MD, MPH Professor of Medicine Mayo Clinic, Jacksonville
Endoscopic and Endobronchial Ultrasound Staging for Lung Cancer Michael B. Wallace, MD, MPH Professor of Medicine Mayo Clinic, Jacksonville Background: Lung Cancer 170,000 cases/yr in U.S. (# 1 cancer)
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationPatients with stage IIIa non-small cell lung cancer
GENERAL THORACIC When is it Best to Repeat a 2-Fluoro-2-Deoxy-D- Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant
More informationIn 1982 Pearson and colleagues [1] from Toronto published
Transition From Mediastinoscopy to Endoscopic Ultrasound for Lung Cancer Staging Mark I. Block, MD Division of Thoracic Surgery, Memorial Healthcare System, Hollywood, Florida Background. Esophageal endoscopic
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationTo allocate patients with non small cell lung cancer
SECTION I: LUNG CANCER DETECTION AND ANALYSIS Endobronchial and Endoscopic Ultrasound-Guided Fine-Needle Aspiration: A Must for Thoracic Surgeons Shawn S. Groth, MD, and Rafael S. Andrade, MD Division
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationRole of EBUS in mediastinal staging of lung cancer. -Dr. Nandakishore Baikunje
Role of EBUS in mediastinal staging of lung cancer -Dr. Nandakishore Baikunje Overview of the seminar Introduction Endosonography to stage the mediastinum Technical aspects of EBUS-TBNA for mediastinal
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationDoes Pneumonectomy Have a Role in the Treatment of Stage IIIA Non-Small Cell Lung Cancer?
Does Pneumonectomy Have a Role in the Treatment of Stage IIIA Non-Small Cell Lung Cancer? Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R. Kelsey, MD, Mark W. Onaitis, MD, Thomas A. D Amico, MD,
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More information